Edivoxetine: Difference between revisions

Latest revision as of 10:53, 23 March 2025

Edivoxetine[edit]

Edivoxetine is a pharmaceutical compound that was under development as a potential treatment for major depressive disorder (MDD). It is classified as a selective norepinephrine reuptake inhibitor (NRI), which means it primarily affects the neurotransmitter norepinephrine in the brain. Edivoxetine was being developed by the pharmaceutical company Eli Lilly and Company.

Pharmacology[edit]

Edivoxetine functions by inhibiting the reuptake of norepinephrine, thereby increasing its availability in the synaptic cleft. This mechanism is thought to contribute to its potential antidepressant effects. Unlike some other antidepressants, edivoxetine does not significantly affect the reuptake of serotonin or dopamine, making it a more selective agent.

Development and Clinical Trials[edit]

Edivoxetine was evaluated in several clinical trials to assess its efficacy and safety in treating major depressive disorder. However, the results from these trials were not sufficiently positive to support its continued development for this indication. The trials indicated that while edivoxetine was generally well-tolerated, its efficacy in alleviating symptoms of depression was not significantly better than placebo.

Potential Uses[edit]

Although its development for major depressive disorder was discontinued, edivoxetine's pharmacological profile suggests it could be explored for other conditions where norepinephrine modulation might be beneficial. These could include attention deficit hyperactivity disorder (ADHD) or certain types of anxiety disorders. However, as of the latest updates, no further development has been reported.

Chemical Properties[edit]

Edivoxetine is a small molecule with a specific chemical structure that allows it to selectively inhibit norepinephrine reuptake. The chemical structure of edivoxetine is depicted in the accompanying images, which illustrate both the structural formula and a ball-and-stick model.

Related Pages[edit]

@@ Line 1: / Line 1: @@
-'''Edivoxetine''' is a [[norepinephrine reuptake inhibitor]] (NRI) that was under investigation for the treatment of major depressive disorder (MDD). Edivoxetine acts by inhibiting the reuptake of [[norepinephrine]], a neurotransmitter associated with mood and attention, thereby increasing its levels in the synaptic cleft and contributing to its antidepressant effects. Despite initial promise in clinical trials, its development was discontinued due to insufficient efficacy in treating depression compared to existing treatments.
+==Edivoxetine==
-==Mechanism of Action==
+[[File:Edivoxetine.svg|Chemical structure of Edivoxetine|thumb|right]]
-Edivoxetine functions by selectively inhibiting the reuptake of norepinephrine in the brain, without significant effects on the reuptake of other neurotransmitters such as [[serotonin]] or [[dopamine]]. This selectivity is thought to contribute to its antidepressant and anxiolytic effects, as norepinephrine plays a key role in regulating mood and anxiety levels.
-==Clinical Trials==
+'''Edivoxetine''' is a pharmaceutical compound that was under development as a potential treatment for [[major depressive disorder]] (MDD). It is classified as a [[selective norepinephrine reuptake inhibitor]] (NRI), which means it primarily affects the neurotransmitter [[norepinephrine]] in the brain. Edivoxetine was being developed by the pharmaceutical company [[Eli Lilly and Company]].
-Clinical trials of edivoxetine evaluated its efficacy and safety in treating major depressive disorder. These studies compared edivoxetine to placebo and, in some cases, to other antidepressant medications. Although edivoxetine demonstrated some antidepressant effects, it failed to show a significant advantage over existing treatments, leading to the discontinuation of its development for depression.
-==Side Effects==
+==Pharmacology==
-The side effects associated with edivoxetine are similar to those of other norepinephrine reuptake inhibitors and may include hypertension, increased heart rate, dry mouth, insomnia, and gastrointestinal disturbances. The drug's safety profile, as observed in clinical trials, was a factor considered in the decision-making process regarding its further development.
-==Development and Discontinuation==
+Edivoxetine functions by inhibiting the reuptake of norepinephrine, thereby increasing its availability in the synaptic cleft. This mechanism is thought to contribute to its potential antidepressant effects. Unlike some other antidepressants, edivoxetine does not significantly affect the reuptake of [[serotonin]] or [[dopamine]], making it a more selective agent.
-Edivoxetine was developed by Eli Lilly and Company, a pharmaceutical company with a history of developing treatments for psychiatric conditions. Despite initial positive results in early clinical trials, phase III trials did not demonstrate a significant improvement in depression symptoms compared to placebo or other antidepressants. As a result, Eli Lilly and Company announced the discontinuation of edivoxetine's development for the treatment of major depressive disorder.
-==Current Status==
+==Development and Clinical Trials==
-As of the last update, there are no ongoing clinical trials investigating the use of edivoxetine for any condition, and the compound is not approved for use in any country. The discontinuation of edivoxetine's development highlights the challenges in developing new and effective treatments for major depressive disorder.
+[[File:Edivoxetine_ball-and-stick_model.png|Ball-and-stick model of Edivoxetine|thumb|left]]
+Edivoxetine was evaluated in several clinical trials to assess its efficacy and safety in treating major depressive disorder. However, the results from these trials were not sufficiently positive to support its continued development for this indication. The trials indicated that while edivoxetine was generally well-tolerated, its efficacy in alleviating symptoms of depression was not significantly better than placebo.
+==Potential Uses==
+Although its development for major depressive disorder was discontinued, edivoxetine's pharmacological profile suggests it could be explored for other conditions where norepinephrine modulation might be beneficial. These could include [[attention deficit hyperactivity disorder]] (ADHD) or certain types of [[anxiety disorders]]. However, as of the latest updates, no further development has been reported.
+==Chemical Properties==
+Edivoxetine is a small molecule with a specific chemical structure that allows it to selectively inhibit norepinephrine reuptake. The chemical structure of edivoxetine is depicted in the accompanying images, which illustrate both the structural formula and a ball-and-stick model.
+==Related Pages==
-==See Also==
-* [[Antidepressant]]
-* [[Norepinephrine reuptake inhibitor]]
 * [[Major depressive disorder]]
-* [[Neurotransmitter]]
+* [[Selective norepinephrine reuptake inhibitor]]
+* [[Eli Lilly and Company]]
+* [[Norepinephrine]]
 [[Category:Antidepressants]]
-[[Category:Norepinephrine reuptake inhibitors]]
+[[Category:Selective norepinephrine reuptake inhibitors]]
-[[Category:Unapproved drugs]]
+[[Category:Drugs not assigned an ATC code]]
-{{medicine-stub}}
-<gallery>
-File:Edivoxetine.svg|Edivoxetine
-File:Edivoxetine_ball-and-stick_model.png|Edivoxetine ball-and-stick model
-</gallery>